All Posts
🤚🏻 Five for Friday – Newly Diagnosed/New to CCF
Home / Blog / [wpbb post:title] If you or a loved one have been diagnosed with cholangiocarcinoma, the Foundation created…
🤚🏻 Five for Friday – January is National Mentoring Month
Home / Blog / [wpbb post:title] The Foundation hopes you are having a Happy New Year! January is National Mentoring…
Monthly Scientific Update – January 2023
Apigenin-Conjugated Gold Nanoparticles: A Potential New Treatment for Cholangiocarcinoma Apigenin is a plant-derived compound that has been explored as a…
🤚🏻 Five for Friday – 7 Milestones from 2022
Home / Blog / [wpbb post:title] Join us in welcoming 2023! It is going to be an extraordinary year. The…
🤚🏻 Five for Friday - Happy Holidays
Home / Blog / [wpbb post:title] As 2022 comes to a close, the Foundation celebrates the significant progress this year…
A single arm phase 2 study of Y-90 SIRT in combination with durvalumab (MEDI 4736) and gemcitabine/cisplatin in locally advanced, unresectable or metastatic intrahepatic cholangiocarcinoma
Study Name A single arm phase 2 study of Y-90 SIRT in combination with durvalumab (MEDI 4736) and gemcitabine/cisplatin in locally advanced,…
🤚🏻 Five for Friday – Stories of Hope
Home / Blog / [wpbb post:title] Cancer can take away a lot of things but never hope. The Foundation honors…
🤚🏻 Five for Friday – Share Gratitude and Give Back
Home / Blog / [wpbb post:title] As the holiday season approaches, we invite you to look for ways to show…
Bruce Coppock, Former Vice Chair of the Board of Directors of the Cholangiocarcinoma Foundation, Dies at age 71
Cholangiocarcinoma patient Bruce Coppock leaves behind a legacy of leadership benefiting the Cholangiocarcinoma Foundation Bruce Coppock, Vice Chair of the…
🤚🏻 Five for Friday – Candles for the Cure 2022
Home / Blog / [wpbb post:title] The tradition continues with 2022 Candles for the Cure. This holiday season, Cholangiocarcinoma Foundation invites…